Klag M J, Whelton P K, Randall B L, Neaton J D, Brancati F L, Ford C E, Shulman N B, Stamler J
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
N Engl J Med. 1996 Jan 4;334(1):13-8. doi: 10.1056/NEJM199601043340103.
End-stage renal disease in the United States creates a large burden for both individuals and society as a whole. Efforts to prevent the condition require an understanding of modifiable risk factors.
We assessed the development of end-stage renal disease through 1990 in 332,544 men, 35 to 57 years of age, who were screened between 1973 and 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). We used data from the national registry for treated end-stage renal disease of the Health Care Financing Administration and from records on death from renal disease from the National Death Index and the Social Security Administration.
During an average of 16 years of follow-up, 814 subjects either died of end-stage renal disease or were treated for that condition (15.6 cases per 100,000 person-years of observation). A strong, graded relation between both systolic and diastolic blood pressure and end-stage renal disease was identified, independent of associations between the disease and age, race, income, use of medication for diabetes mellitus, history of myocardial infarction, serum cholesterol concentration, and cigarette smoking. As compared with men with an optimal level of blood pressure (systolic pressure < 120 mm Hg and diastolic pressure < 80 mm Hg), the relative risk of end-stage renal disease for those with stage 4 hypertension (systolic pressure > or = 210 mm Hg or diastolic pressure > or = 120 mm Hg) was 22.1 (P < 0.001). These relations were not due to end-stage renal disease that occurred soon after screening and, in the 12,866 screened men who entered the MRFIT study, were not changed by taking into account the base-line serum creatinine concentration and urinary protein excretion. The estimated risk of end-stage renal disease associated with elevations of systolic pressure was greater than that linked with elevations of diastolic pressure when both variables were considered together.
Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure.
在美国,终末期肾病给个人和整个社会都带来了沉重负担。预防该疾病需要了解可改变的风险因素。
我们评估了1990年时332544名年龄在35至57岁之间男性的终末期肾病发病情况,这些男性在1973年至1975年期间接受了筛查,以纳入多重危险因素干预试验(MRFIT)。我们使用了医疗保健财务管理局的全国终末期肾病治疗登记数据以及国家死亡指数和社会保障管理局的肾病死亡记录数据。
在平均16年的随访期间,814名受试者死于终末期肾病或接受了该疾病的治疗(每100000人年观察期有15.6例)。收缩压和舒张压与终末期肾病之间均存在强烈的分级关系,且独立于该疾病与年龄、种族、收入、糖尿病用药情况、心肌梗死病史、血清胆固醇浓度和吸烟之间的关联。与血压处于最佳水平(收缩压<120 mmHg且舒张压<80 mmHg)的男性相比,4期高血压(收缩压≥210 mmHg或舒张压≥120 mmHg)患者发生终末期肾病的相对风险为22.1(P<0.001)。这些关系并非由于筛查后不久发生的终末期肾病所致,在12866名进入MRFIT研究的筛查男性中,考虑基线血清肌酐浓度和尿蛋白排泄情况后,这些关系并未改变。当同时考虑这两个变量时,与收缩压升高相关的终末期肾病估计风险大于与舒张压升高相关的风险。
血压升高是终末期肾病的一个强大独立危险因素;预防该疾病的干预措施需要强调预防和控制正常高值血压和高血压。